Summary
High-dose busulphan-containing chemotherapy regimens have shown high response rates in children with relapsed or refractory neuroblastoma, Ewing’s sarcoma and medulloblastoma. However, the anti-tumour activity of busulfan as a single agent remains to be defined, and this was evaluated in athymic mice bearing advanced stage subcutaneous paediatric solid tumour xenografts. Because busulphan is highly insoluble in water, the use of several vehicles for enteral and parenteral administration was first investigated in terms of pharmacokinetics and toxicity. The highest bioavailability was obtained with busulphan in DMSO administered i.p. When busulphan was suspended in carboxymethylcellulose and given orally or i.p., the bioavailability was poor. Then, in the therapeutic experiments, busulphan in DMSO was administered i.p. on days 0 and 4. At the maximum tolerated total dose (50 mg kg–1), busulphan induced a significant tumour growth delay, ranging from 12 to 34 days in the three neuroblastomas evaluated and in one out of three medulloblastomas. At a dose level above the maximum tolerated dose, busulphan induced complete and partial tumour regressions. Busulphan was inactive in a peripheral primitive neuroectodermal tumour (PNET) xenograft. When busulphan pharmacokinetics in mice and humans were considered, the estimated systemic exposure at the therapeutically active dose in mice (113 μg h ml–1) was close to the mean total systemic exposure in children receiving high-dose busulphan (102.4 μg h ml–1). In conclusion, busulphan displayed a significant anti-tumour activity in neuroblastoma and medulloblastoma xenografts at plasma drug concentrations which can be achieved clinically in children receiving high-dose busulphan-containing regimens.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aaron, R. H., Elion, G. B., Colvin, O. M., Graham, M., Keir, S., Bigner, D. D. & Friedman, H. S. (1994). Busulfan therapy of central nervous system xenografts in athymic mice. Cancer Chemother Pharmacol 35: 127–131.
Arduino, L. J. & Mellinger, G. T. (1967). Clinical trial of busulfan (NSC-750) in advanced carcinoma of prostate. Cancer Chemother Rep 51: 295–304.
Berger, D. P., Winterhalter, B. R., Dengler, W. A. & Fiebig, H. H. (1992). Preclinical activity of hepsulfam and busulfan in solid human tumor xenografts and human bone marrow. Anticancer Drugs 3: 531–539.
Bettan-Renaud, L., Bayle, C., Teyssier, J. R. & Benard, J. (1989). Stability of phenotypic and genotypic traits during the establishment of a human neuroblastoma cell line, IGR-N-835. Int J Cancer 44: 460–466.
Bhagwatwar, H. P., Phadungpojna, S., Chow, D. S. L. & Anderson, B. S. (1996). Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol 37: 401–408.
Bhoopalam, N., Price, K. S., Norgello, H. & Fried, W. (1985). Busulfan-induced suppression of natural killer cell activity. Exp Hematol 13: 1127–1132.
Bishop, J. B. & Wassom, J. S. (1986). Toxicological review of busulfan (Myleran). Mutat Res 168: 15–45.
Demirer, T., Buckner, C. D., Appelbaum, F. R., Clift, R., Strob, R., Myerson, D., Lilleby, K., Rowley, S. & Bensinger, W. I. (1996). High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. Bone Marrow Transplant 17: 769–774.
Down, J. D., Berman, A. J., Warhol, M., Van Dijken, P. J., Ferrara, J. L. M., Yeap, B., Hellman, S. & Mauch, P. M. (1989). Late tissue-specific toxicity of total body irradiation and busulfan in a murine bone marrow transplant model. Int J Radiat Oncol Biol Phys 17: 109–116.
Dunn, C. R. (1974). The chemical and biological properties of busulphan (Myleran). Exp Hematol 2: 101–117.
Dupuis-Girod, S., Hartmann, O., Benhamou, E., Doz, F., Mechinaud, F., Bouffet, E., Coze, C. & Kalifa, C. (1996). Will high-dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma?. J Neurooncol 25: 87–89.
Hartmann, O., Benhamou, E., Beaujean, F., Pico, J. L., Kalifa, C., Patte, C., Flamant, F. & Lemerle, J. (1986). High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. J Clin Oncol 4: 1804–1810.
Hartmann, O., Valteau-Couanet, D., Lapierre, V., Couanet, D., Lumbroso, J. & Benhamou, E. (1997). Stage IV neuroblastoma over 1 year of age autografted: the combination used in the conditioning regimen is the major prognostic factor. Med Ped Oncol 20: 320
Hassan, M., Öberg, G., Ericson, K., Ehrsson, H., Eriksson, L., Ingvar, M., Stone-Elander, S., Thorell, J-O, Smedmyr, B., Warne, N. & Widen, L. (1992). In vivo distribution of [11C]-busulfan in cynomolgus monkey and in the brain of a human patient. Cancer Chemother Pharmacol 30: 81–85.
Josvasen, N. & Boyum, A. (1973). Haematopoiesis in busulphan-treated mice. A comparison between two different stem cell assays. Scand J Haematol 11: 78–86.
Kalifa, C., Hartmann, O., Demeocq, F., Vassal, G., Couanet, D., Terrier-Lacombe, M. J., Valteau, D., Brugieres, L. & Lemerle, J. (1992). High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant 9: 227–233.
Ladenstein, R., Hartmann, O., Pinkerton, R., Michon, J., Garaventa, A., Rosti, G. & Philip, T. (1997). The impact of megatherapy followed by stem cell reinfusion in Ewing tumour patients with residual disease. Bone Marrow Transplant 19: S86
MacCracken, III C. H., Lottsfeldt, J. L. & Lee, M. Y. (1988). Concurrent activation of granulocytes and osteoclasts in busulfan-suppressed bone marrow in response to transplantation of a mammary carcinoma in mice. Exp Hematol 16: 285–288.
Mattern, J., Bak, M., Hahn, E. W. & Volm, M. (1988). Human tumor xenografts as a model for drug testing. Cancer Metastasis Rev 7: 263–284.
Millar, J. L., Hudspith, B. N. & Blackett, N. M. (1975). Reduced lethality in mice receiving a combined dose of cyclophosphamide and busulphan. Br J Cancer 32: 193–198.
Smalowski, W. E., Araneo, B. A., Butler, M. O., Fung, M. C. & Jonhson, H. M. (1989). Peripheral lymph node helper T-cell recovery after syngeneic bone marrow transplantation in mice prepared with either γ-irradiation or busulfan. Blood 74: 1436–1445.
Sullivan, R. (1958). Myleran therapy in bronchogenic carcinoma. Ann NY Acad Sci 68: 1038–1046.
Tutschka, P. J. & Santos, G. W. (1977). Bone marrow transplantation in the busulfan-treated rat. III. Relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients. Transplantation 24: 52–62.
Vassal, G., Re, M. & Gouyette, A. (1988). Gas chromatographic–mass spectometric assay for busulfan in biological fluids using a deuterated internal standard. J Chromatog 428: 357–361.
Vassal, G., Deroussent, A., Hartmann, O., Challine, D., Benhamou, E., Valteau-Couanet, D., Brugieres, L., Kalifa, C., Gouyette, A. & Lemerle, J. (1990). Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 50: 6203–6207.
Vassal, G., Deroussent, A., Challine, D., Hartmann, O., Koscielny, S., Valteau-Couanet, D., Lemerle, J. & Gouyette, A. (1992). Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?. Blood 79: 2475–2479.
Vassal, G., Challine, D., Koscielny, S., Hartmann, O., Deroussent, A., Valteau-Couanet, D., Lemerle, J., Levi, F. & Gouyette, A. (1993). Chronopharmacology of high-dose busulfan in children. Cancer Res 53: 1534–1537.
Vassal, G., Terrier-Lacombe, M. J., Lellouch-Tubiana, A., Valery, C. A., Sainte-Rose, C., Morizet, J., Ardouin, P., Riou, G., Kalifa, C. & Gouyette, A. (1996a). Tumorigenicity of cerebellar primitive neuro-ectodermal tumors in athymic mice correlates with poor prognosis in children. Int J Cancer (Pediatr Oncol) 69: 146–151.
Vassal, G., Terrier-Lacombe, M. J., Bissery, M. C., Venuat, A. M., Gyergyay, F., Benard, J., Morizet, J., Boland, I., Ardouin, P., Bressac-De-Paillerets, B. & Gouyette, A. (1996b). Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 74: 537–545.
Vassal, G., Boland, I., Santos, A., Bissery, M. C., Terrier-Lacombe, M. J., Morizet, J., Sainte-Rose, C., Lellouch-Tubiana, A., Kalifa, C. & Gouyette, A. (1997). Potent therapeutic activity of irinotecan (CPT-11) and its schedule-dependency in medulloblastoma xenografts in nude mice. Int J Cancer 73: 156–163.
Yeager, A. M., Shinohara, M. & Shinn, C. (1991). Hematopoietic cell transplantation after administration of high-dose busulfan in murine globoid cell leukodystrophy (the Twitcher mouse). Pediatr Res 29: 302–305.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Boland, I., Vassal, G., Morizet, J. et al. Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations. Br J Cancer 79, 787–792 (1999). https://doi.org/10.1038/sj.bjc.6690126
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690126
Keywords
This article is cited by
-
Medulloblastoma in childhood: revisiting intrathecal therapy in infants and children
Cancer Chemotherapy and Pharmacology (2010)
-
Preclinical studies of treosulfan demonstrate potent activity in Ewing’s sarcoma
Cancer Chemotherapy and Pharmacology (2008)
-
High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy
Bone Marrow Transplantation (2005)
-
Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma
Bone Marrow Transplantation (2000)